Bath & Body Works Q2 net sales fall amid weak underlying demand
Bath & Body Works reported Q2 net sales of $1.51bn, down 2.3% YoY, but higher operating income ($216m) and net income ($118m). CEO Daniel Heaf noted sequential improvements in body care and digital sales, while raising full-year 2026 EPS outlook to $3.13-$3.33. The company expects Q3 sales to decline 5-2.5% with adjusted EPS at $0.07-$0.12.
How this was made

The 30-second read
Why it matters
The earnings beat and raised EPS guidance may prompt short‑term buying interest, while the sales decline signals ongoing demand challenges.
Market read
First‑report earnings with guidance lift; primary driver for short‑term price movement.
What to watch
International revenue growth and direct‑sales momentum could offset US weakness.
Background
Bath & Body Works is a leading personal care and home fragrance retailer, part of the consumer discretionary sector.
Ticker impact
Bath & Body Works reported Q2 net sales decline and raised full-year EPS guidance.
Potential modest rally on guidance lift.
Guidance raise signals improved profitability despite sales dip, likely to be well‑received by investors.
Market effects
Consumer discretionary retailers may see mixed sentiment as sales pressure persists.
U.S. consumer spending outlook could be adjusted modestly.
Limited, primarily U.S. retail sector.
Counterpoint
Sales decline may outweigh guidance lift, suggesting caution.
Key entities
- companyBath & Body Works
U.S. retailer reporting Q2 results.




